Steven Cohen’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.36M | Sell |
238,776
-719,125
| -75% | -$3.26M | ﹤0.01% | 2633 |
|
|
2026
Q1 | $4.31M | Sell |
957,901
-274,767
| -22% | -$1.43M | 0.01% | 1796 |
|
|
2025
Q4 | $7.58M | Buy |
1,232,668
+158,705
| +15% | +$1.15M | 0.01% | 1534 |
|
|
2025
Q3 | $7.76M | Buy |
1,073,963
+535,903
| +100% | +$3.18M | 0.01% | 901 |
|
|
2025
Q2 | $2.86M | Buy |
538,060
+353,060
| +191% | +$2.09M | 0.01% | 1164 |
|
|
2025
Q1 | $1.64M | Sell |
185,000
-163,604
| -47% | -$1.96M | ﹤0.01% | 1304 |
|
|
2024
Q4 | $4.78M | Sell |
348,604
-715,107
| -67% | -$13.2M | 0.01% | 965 |
|
|
2024
Q3 | $29.1M | Buy |
1,063,711
+224,255
| +27% | +$6.07M | 0.07% | 314 |
|
|
2024
Q2 | $20.5M | Buy |
839,456
+61,260
| +8% | +$1.34M | 0.05% | 395 |
|
|
2024
Q1 | $16.6M | Buy |
+778,196
| New | +$16.7M | 0.04% | 525 |
|
|
2023
Q4 | – | Sell |
-2,636
| Closed | -$42.3K | – | 2582 |
|
|
2023
Q3 | $42.3K | Buy |
2,636
+2,601
| +7,431% | +$49.5K | ﹤0.01% | 2169 |
|
|
2023
Q2 | $816 | Buy |
+35
| New | +$764 | ﹤0.01% | 2008 |
|
|
2023
Q1 | – | Sell |
-26,800
| Closed | -$389K | – | 2439 |
|
|
2022
Q4 | $389K | Sell |
26,800
-377,608
| -93% | -$7.04M | ﹤0.01% | 1174 |
|
|
2022
Q3 | $7.72M | Buy |
404,408
+175,163
| +76% | +$4.02M | 0.03% | 590 |
|
|
2022
Q2 | $4.17M | Buy |
229,245
+81,648
| +55% | +$1.7M | 0.02% | 754 |
|
|
2022
Q1 | $3.72M | Buy |
+147,597
| New | +$3.78M | 0.01% | 763 |
|
|
2021
Q4 | – | Sell |
-239,493
| Closed | -$7.73M | – | 1226 |
|
|
2021
Q3 | $7.73M | Sell |
239,493
-142,312
| -37% | -$4.73M | 0.03% | 546 |
|
|
2021
Q2 | $11.7M | Sell |
381,805
-16,043
| -4% | -$464K | 0.05% | 414 |
|
|
2021
Q1 | $12.1M | Buy |
397,848
+28,740
| +8% | +$816K | 0.06% | 386 |
|
|
2020
Q4 | $7.3M | Buy |
369,108
+345,029
| +1,433% | +$5.57M | 0.04% | 513 |
|
|
2020
Q3 | $314K | Buy |
+24,079
| New | +$305K | ﹤0.01% | 850 |
|
|
2020
Q2 | – | Sell |
-141,500
| Closed | -$2.02M | – | 943 |
|
|
2020
Q1 | $2.02M | Buy |
141,500
+124,839
| +749% | +$2.64M | 0.02% | 504 |
|
|
2019
Q4 | $454K | Sell |
16,661
-121,253
| -88% | -$3.34M | ﹤0.01% | 781 |
|
|
2019
Q3 | $3.95M | Sell |
137,914
-844,687
| -86% | -$24.6M | 0.02% | 496 |
|
|
2019
Q2 | $27.3M | Buy |
982,601
+359,488
| +58% | +$10.2M | 0.14% | 181 |
|
|
2019
Q1 | $20.7M | Sell |
623,113
-313,394
| -33% | -$9.54M | 0.09% | 242 |
|
|
2018
Q4 | $27.2M | Buy |
936,507
+326,187
| +53% | +$11.7M | 0.13% | 195 |
|
|
2018
Q3 | $28.1M | Sell |
610,320
-225,880
| -27% | -$10M | 0.12% | 226 |
|
|
2018
Q2 | $31.2M | Sell |
836,200
-46,674
| -5% | -$1.58M | 0.12% | 209 |
|
|
2018
Q1 | $26.1M | Buy |
882,874
+18,926
| +2% | +$640K | 0.11% | 243 |
|
|
2017
Q4 | $29.7M | Buy |
+863,948
| New | +$29.1M | 0.13% | 219 |
|
|
2015
Q2 | – | Sell |
-153,400
| Closed | -$5.43M | – | 805 |
|
|
2015
Q1 | $5.43M | Sell |
153,400
-206,900
| -57% | -$7.41M | 0.04% | 426 |
|
|
2014
Q4 | $12.3M | Buy |
+360,300
| New | +$12.8M | 0.09% | 291 |
|
Other funds holding MYGN
VPC
Steven Cohen's MYGN Position: Q2 2026 in Review
Steven Cohen reduced its Myriad Genetics (MYGN) stake by 75% in Q2 2026, selling an estimated $3.26M and leaving 238,776 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2633.
Steven Cohen first reported a position in MYGN in Q4 2014 and has held it in 33 quarters since. The position peaked at $31.2M in Q2 2018. 195 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.
- Steven Cohen held 238,776 shares of Myriad Genetics worth $1.36M as of Q2 2026.
- Steven Cohen sold 719,125 Myriad Genetics shares in Q2 2026, an estimated $3.26M.
- Myriad Genetics made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #2633 holding.
- Steven Cohen first reported a position in Myriad Genetics in Q4 2014 and has held it in 33 quarters since.
- Steven Cohen's Myriad Genetics position peaked at $31.2M in Q2 2018.
- 195 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.
Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.